Clinical trials: Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy
This is a prospective single-arm clinical study to evaluate the role of NAC after chemotherapy among patients with AML can promote hematopoietic recovery and does not affect the remission rate of the leukemia.
- Trial name
- NCT06024031
- Testing
- N-acetyl-L-cysteine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
- Trial name
- NCT00309907
- Testing
- etanercept, methylprednisolone
- Where
- 26 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Whether Idarubicin can overcomes multidrug resistant 1 induced chemoresistance with higher induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen has a…
- Trial name
- NCT01889407
- Testing
- Idarubicin
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
The present project is a multicenter, phase II trial which aims at evaluating if the administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could improve the response rate to DLI in the population of…
- Trial name
- NCT02017457
- Testing
- Donor lymphocyte infusion, Azacytidine
- Where
- 12 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Carlos Graux, MD, PhD
Leukemia, Myeloid, Acute
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
The goal of this clinical research study is to evaluate the safety and efficacy of Azacytidine in combination with Venetoclax in patients with newly diagnosed fit acute myeloid leukemia.
- Trial name
- NCT05471700
- Testing
- Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhujiang Hospital
Acute Myeloid Leukemia
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.
- Trial name
- NCT00822094
- Testing
- CPX-351, Intensive Salvage Therapy
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia
The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)
This study is a phase II randomized multicenter study. Patients will be enrolled at time of diagnosis and will receive one or two cycles of induction chemotherapy.
- Trial name
- CLARA (NCT00932412)
- Testing
- CLARA, HDAc
- Where
- 34 sites in France
- Volunteers
- 735 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia, Non-M3 Acute Myeloid Leukemia
Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML
This prospective cohort study aims to evaluate the prognostic significance of the C-reactive protein-to-albumin ratio (CAR), albumin-to-fibrinogen ratio (AFR), and serum ferritin level in newly diagnosed de novo non-M3 acute…
- Conditions
- Acute Myeloid Leukemia, Non-M3 Acute Myeloid Leukemia, De Novo Acute Myeloid Leukemia With Multilineage Dysplasia
- Trial name
- NCT07810829
- Volunteers
- 208 people
- Sponsor
- Assiut University
Leukemia
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372619
- Testing
- clofarabine, cytarabine, methotrexate
- Where
- 79 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Sirolimus, tacrolimus, and methotrexate may be effective in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00089037
- Testing
- methotrexate, sirolimus, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
This phase II trial is studying how well lenalidomide works in treating older patients with acute myeloid leukemia with abnormal chromosome 5q.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00352365
- Testing
- lenalidomide
- Where
- 54 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Kidney Cancer
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who…
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00036712
- Testing
- management of therapy complications, pain therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Acute Myelogenous Leukemia, Myelodysplasia
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
The purpose of this study is to test the safety of a new investigational acute myeloblastic leukemia (AML) vaccine and see what effects (good and bad) it has on patients with advanced myelodysplasia or acute myelogenous leukemia.
- Trial name
- NCT00136422
- Testing
- autologous tumor cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
This study is designed in its first part (phase Ib) to determine the recommended dose of the OTX015 + Vidaza (azacitidine) combination in newly diagnosed acute myeloid leukemia patients not candidate for standard intensive…
- Trial name
- NCT02303782
- Testing
- OTX015, Vidaza (azacitidine)
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Myeloid Leukemia
Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia
This study is an open-label phase II trial to investigate the efficacy and toxicity of low-dose decitabine (5-aza-2'-deoxycytidine) in elderly patients with acute myeloid leukemia (AML) not eligible for aggressive induction…
- Trial name
- NCT00866073
- Testing
- Decitabine 15 mg/m2 i.v.
- Where
- 8 sites in Germany, Netherlands
- Volunteers
- 238 people
- Sponsor
- University Hospital Freiburg
Acute Myeloid Leukemia
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).
- Trial name
- NCT05471323
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to…
- Trial name
- NCT00651261
- Testing
- cytarabine, daunorubicin, midostaurin
- Where
- 176 sites in United States, Canada
- Volunteers
- 717 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Blood Stem Cell Transplant Failure, Leukemia
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
The goal of this clinical research study is to learn about the safety of giving a stem cell transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with certain types of blood disorders or blood…
- Conditions
- Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
- Trial name
- NCT01010217
- Testing
- Cyclophosphamide, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- M.D. Anderson Cancer Center
Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome, Acute Myeloid Leukemia, in Relapse
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Phase II open-label single-arm prospective multicentric clinical trial of PF-05212384 (PKI-587) delivered by intravenous route. A 2-stage Fleming design will be employed.
- Conditions
- Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome, Acute Myeloid Leukemia, in Relapse, de Novo Acute Myeloid Leukemia at Diagnostic
- Trial name
- 5 (NCT02438761)
- Testing
- PF-05212384
- Where
- 5 sites in France
- Volunteers
- 10 people
- Sponsor
- Institut Curie